UPDATE: Vessix in hand, Boston Scientific targets Medtronic in high blood pressure market

November 8, 2012 by MassDevice staff

Boston Scientific executives tell MassDevice.com that the medical device company is aiming to have the 2nd renal denervation high blood pressure device on the U.S. market, behind arch-rival Medtronic, now that it's agreed to pay up to $425 million for Vessix Vascular.

Boston Scientific acquires Vessix

Boston Scientific (NYSE:BSX) is confident that it will be the 2nd player in the U.S. market for renal denervation, executives told MassDevice.com today, stressing their belief that the Vessix Vascular high blood pressure treatment acquired today is superior to competing offerings from arch-rivals Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ).

"We believe we'll be 2nd to market with a highly differentiated technology, a true 2nd-generation device," Jeff Mirviss, president Boston's peripheral interventions business," told MassDevice.com today.

Laguna Hills, Calif.-based Vessix makes the V2 renal denervation system. Boston Scientific agreed today to pay up to $425 million for Vessix, with a $125 million up-front payment and another $300 million in milestone payments out to 2017.

Sign up to get our free newsletters delivered straight to your inbox